Why PSA levels reflect prostate cancer progressionJanuary 14th, 2011 - 6:38 pm ICT by ANI
Washington, Jan 14 (ANI): Researchers studying prostate cancer cells for decades have now found why PSA (prostate-specific antigen) levels reflect cancer progression.
“This is the first demonstration of a mechanism that explains why PSA is a bad thing for a tumour to produce,” said senior author Sal Pizzo, chair of the Duke Department of Pathology.
“I am willing to bet there is also a connection in cancerous cell growth with this particular biological signalling mechanism happening in other types of cells,” he added.
Using human prostate cancer cells in a laboratory culture, the team found that an antibody, called alpha2-macroglobulin (a2M), reacts with a cell surface receptor called GRP78 on the cancer cells to produce more PSA.
The PSA forms a complex with the antibody that also binds to the GRP78 receptor, and that activates several key pathways, which stimulate cancer cell growth and cell movement and block cell death.
The study bolsters the case for measuring PSA as a marker of tumour progression, as well as for monitoring for a2M antibody levels.
“I personally believe PSA is more useful as a progression marker, particularly with a baseline value on record at the time of the original therapy. A rapidly rising value and/or a very high value is reason for concern. I also believe that monitoring the serum for the appearance of antibodies directed against GRP78 is also a good marker of progression,” said Pizzo.
He said that the findings could yield cancer therapies that block the a2M-PSA complex from stimulating the cell receptor signalling cascade, and that his laboratory is investigating possibilities.
The findings might also yield new kinds of early-detection tests for prostate cancer.
Pizzo credits lead author Uma Misra with deducing that PSA may be involved in a signalling feedback loop that promotes more aggressive behaviour in the human prostate cancer cells.
Years ago, Misra discovered the GRP78 receptor on the prostate tumor cell surface, the receptor that binds the a2M antibody and the a2M-PSA complex.
“We were surprised to find that this complex binds with the protein GRP78, because we thought the GRP78 molecule only lived deep inside the cell, where it was busy taking improperly folded proteins and helping them to fold properly,” said Pizzo.
The study is published in the current edition of the Journal of Biological Chemistry. (ANI)
- New method detects aggressive prostate cancer - Aug 09, 2012
- Potential therapeutic target across a range of cancer types found - Oct 21, 2010
- Beer may prevent prostate cancer - Dec 09, 2009
- PSA test more reliable in men taking prostate-shrinking drug - Dec 18, 2010
- New drugs to kill cancers minus side-effects - May 21, 2012
- Key enzyme that controls growth of breast cancer cells identified - Nov 19, 2010
- Mice study shows promise against final stages of terminal cancer - Oct 07, 2010
- Protein that protects against prostate cancer discovered - Feb 01, 2011
- Experimental drug for advanced prostate cancer shows promise - Apr 15, 2010
- Early warning signs for prostate cancer identified - Nov 07, 2010
- New research paves way for better Graves' disease treatment - Dec 02, 2010
- Gene fusion is the 'smoking gun' in the development of prostate cancer: Study - May 19, 2010
- New drug effective against breast tumours - Dec 13, 2009
- Simple test could save prostate cancer patients from surgery - Feb 09, 2011
- Molecule discovery good news for prostate cancer sufferers - Dec 29, 2009
Tags: aggressive behaviour, antibody levels, baseline value, cancer cell growth, cancer therapies, cancerous cell growth, cell receptor, cell surface receptor, detection tests, duke department, human prostate cancer, laboratory culture, misra, pizzo, prostat, prostate cancer, prostate cancer cells, prostate cancer progression, prostate specific antigen, psa levels